Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma

Journal of Hepatology

Volumn 67, Issue 1, 2017, Pages 32-39

  Beste, Lauren A ^a,b   Green, Pamela K ^a   Berry, Kristin ^a   Kogut, Matthew J ^a,b   Allison, Stephen K ^a,b   Ioannou, George N ^a,b  

^a Veterans Affairs Puget Sound Health Care System   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ledipasvir sofosbuvir; Liver transplant; Paritaprevir ritonavir ombitasvir and dasabuvir; Sustained virologic response

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; SORAFENIB; ANTIVIRUS AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ALCOHOLISM; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; VETERAN; VIRUS LOAD; AGED; LIVER TUMOR; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; VETERANS;

EID: 85017193924     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.02.027     Document Type: Article

References (44)

1. Ryerson, A.B., Eheman, C.R., Altekruse, S.F., Ward, J.W., Jemal, A., Sherman, R.L., et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer, 2016.
2. Beste, L.A., Leipertz, S.L., Green, P.K., Dominitz, J.A., Ross, D., Ioannou, G.N., Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology, 2015.
3. El-Serag, H.B., Mason, A.C., Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160 (2000), 3227–3230.
4. Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521 521 e511–516.
5. Manns, M., Samuel, D., Gane, E.J., Mutimer, D., McCaughan, G., Buti, M., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis, 2016.
6. Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
7. Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
8. Curry, M.P., Forns, X., Chung, R.T., Terrault, N.A., Brown, R. Jr., Fenkel, J.M., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology, 148(100–107), 2015, e101.
9. AASLD/IDSA/IAS–USA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. [cited 10/9/2015]; Available from: http://www.hcvguidelines.org.
10. Belli, L.S., Berenguer, M., Cortesi, P.A., Strazzabosco, M., Rockenschaub, S.R., Martini, S., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 65 (2016), 524–531.
11. Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.
12. Kanogawa, N., Ogasawara, S., Chiba, T., Saito, T., Motoyama, T., Suzuki, E., et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol 30 (2015), 1197–1204.
13. Hsu, Y.C., Ho, H.J., Wu, M.S., Lin, J.T., Wu, C.Y., Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology (Baltimore, MD) 58 (2013), 150–157.
14. Harada, N., Hiramatsu, N., Oze, T., Tatsumi, T., Hayashi, N., Takehara, T., Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma—a retrospective multicenter study. J Med Virol 87 (2015), 1199–1206.
15. Shirabe, K., Sugimachi, K., Harada, N., Kayashima, H., Maeda, T., Tsujita, E., et al. Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma. Anticancer Res 35 (2015), 6963–6969.
16. Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., Falck-Ytter, Y., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
17. Reig, M., Marino, Z., Perello, C., Inarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
18. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
19. Pol, S., Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 65 (2016), 734–740.
20. Yang, J.D., Aqel, B.A., Pungpapong, S., Gores, G.J., Roberts, L.R., Leise, M.D., Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 65 (2016), 859–860.
21. Corporate Data Warenouse (CDW). March 28, 2014 [cited Feb 2, 2016.]; Available from: http://www.hsrd.research.va.gov/for_researchers/vinci/cdw.cfm.
22. Beste, L.A., Ioannou, G.N., Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev 37 (2015), 131–143.
23. Kramer, J.R., Davila, J.A., Miller, E.D., Richardson, P., Giordano, T.P., El-Serag, H.B., The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Alimentary pharmacol Therapeut 27 (2008), 274–282.
24. Kramer, J.R., Giordano, T.P., Souchek, J., Richardson, P., Hwang, L.Y., El-Serag, H.B., The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. Veterans with hepatitis C. Am J Gastroenterol 100 (2005), 56–63.
25. Ioannou, G.N., Splan, M.F., Weiss, N.S., McDonald, G.B., Beretta, L., Lee, S.P., Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 938–945 945 e931–934.
26. Davila, J.A., Henderson, L., Kramer, J.R., Kanwal, F., Richardson, P.A., Duan, Z., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 154 (2011), 85–93.
27. Ioannou, G.N., Bryson, C.L., Weiss, N.S., Miller, R., Scott, J.D., Boyko, E.J., The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 57 (2013), 249–257.
28. Beste, L.A., Leipertz, S.L., Green, P.K., Dominitz, J.A., Ross, D., Ioannou, G.N., Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology 149 (2015), 1471–1482 e1475; quiz e1417–1478.
29. Rajbhandari, R., Simon, R.E., Chung, R.T., Ananthakrishnan, A.N., Racial disparities in inhospital outcomes for hepatocellular carcinoma in the United States. Mayo Clin Proc 91 (2016), 1173–1182.
30. Kramer, J.R., Kanwal, F., Richardson, P., Giordano, T.P., Petersen, L.A., El-Serag, H.B., Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 106 (2011), 483–491.
31. Beste, L.A., Ioannou, G.N., Larson, M.S., Chapko, M., Dominitz, J.A., Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 8 (2010), 972–978.
32. Backus, L.I., Boothroyd, D.B., Phillips, B.R., Mole, L.A., Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology (Baltimore, MD) 46 (2007), 37–47.
33. Kanwal, F., Hoang, T., Kramer, J.R., Asch, S.M., Goetz, M.B., Zeringue, A., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology, 140(1182–1188), 2011, e1181.
34. Miller, D.R., Safford, M.M., Pogach, L.M., Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 27:Suppl 2 (2004), B10–21.
35. Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 46 (2007), 32–36.
36. Yoshida, E.M., Sulkowski, M.S., Gane, E.J., Herring, R.W. Jr., Ratziu, V., Ding, X., et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 61 (2015), 41–45.
37. Wirth, T.C., Manns, M.P., The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 27 (2016), 1467–1474.
38. Hengst, J., Falk, C.S., Schlaphoff, V., Deterding, K., Manns, M.P., Cornberg, M., et al. DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis, 2016.
39. Wilder, J.M., Jeffers, L.J., Ravendhran, N., Shiffman, M.L., Poulos, J., Sulkowski, M.S., et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology 63 (2016), 437–444.
40. VIEKIRA PAK [package insert]. North Chicago, IL: AbbVie Inc. [cited August 8, 2016.]; Available from: https://www.viekirahcp.com/.
41. Ioannou, G.N., Beste, L.A., Chang, M.F., Green, P.K., Lowy, E., Tsui, J.I., et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology, 151(457–471), 2016, e455.
42. Charlton, M., Gane, E., Manns, M.P., Brown, R.S. Jr., Curry, M.P., Kwo, P.Y., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
43. Forns, X., Charlton, M., Denning, J., McHutchison, J.G., Symonds, W.T., Brainard, D., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (Baltimore, MD) 61 (2015), 1485–1494.
44. Kwo, P.Y., Mantry, P.S., Coakley, E., Te, H.S., Vargas, H.E., Brown, R. Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 371 (2014), 2375–2382.